|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 89.34 | 104.64 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Sep 2023 | Jun 2023 | Dec 2022 | Sep 2022 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | UnAudited | Net Sales | 0 | 0 | 0 | 264.80 | Total Expenditure | 46.88 | 43.13 | 47.27 | 289.80 | PBIDT (Excl OI) | -46.88 | -43.13 | -47.27 | -25.00 | Other Income | 1.64 | 1.02 | 1.02 | 3.20 | Operating Profit | -45.24 | -42.11 | -46.25 | -21.81 | Interest | 20.87 | 17.21 | 16.68 | 17.42 | Exceptional Items | 0 | 0 | 0 | 0 | PBDT | -66.11 | -59.32 | -62.93 | -39.23 | Depreciation | 0.34 | 0.34 | 0.37 | 0.36 | Profit Before Tax | -66.45 | -59.66 | -63.30 | -39.59 | Tax | -17.28 | -13.80 | -16.45 | -8.76 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | -49.17 | -45.86 | -46.85 | -30.83 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | -49.17 | -45.86 | -46.85 | -30.83 | Equity Capital | 431.80 | 431.80 | 431.80 | 431.80 | Face Value (IN RS) | 10 | 10 | 10 | 10 | Reserves | | | | | Calculated EPS | -1.14 | -1.06 | -1.08 | -0.71 | Calculated EPS (Annualised) | -4.55 | -4.25 | -4.34 | -2.86 | No of Public Share Holdings | 17,594,000.00 | 17,594,000.00 | 17,594,000.00 | 17,594,000.00 | % of Public Share Holdings | 40.75 | 40.75 | 40.75 | 40.75 | | | | | | PBIDTM% (Excl OI) | 0 | 0 | 0 | -9.44 | PBIDTM% | 0 | 0 | 0 | -8.24 | PBDTM% | 0 | 0 | 0 | -14.81 | PBTM% | 0 | 0 | 0 | -14.95 | PATM% | 0 | 0 | 0 | -11.64 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|